7B3Y

Structure of a nanoparticle for a COVID-19 vaccine candidate

7B3Y の概要

• エントリーDOI: 10.2210/pdb7b3y/pdb
• EMDBエントリー: 11997
• 分子名称: Fibronectin binding protein,2-dehydro-3-deoxyphosphogluconate aldolase/4-hydroxy-2-oxoglutarate aldolase (1 entity in total)
• 機能のキーワード: sars-cov-2, spytag, vlp, receptor-binding domain, vaccine, covid-19, spycatcher, nanocage, icosahedral, nanoparticle, coronavirus, mi3, virus like particle
• 由来する生物種: Streptococcus pyogenes serotype M49 (strain NZ131); 詳細
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 36000.71

構造登録者

Duyvesteyn, H.M.E.,Stuart, D.I. (登録日: 2020-12-01, 公開日: 2021-01-13, 最終更新日: 2024-11-13)

主引用文献

Tan, T.K.,Rijal, P.,Rahikainen, R.,Keeble, A.H.,Schimanski, L.,Hussain, S.,Harvey, R.,Hayes, J.W.P.,Edwards, J.C.,McLean, R.K.,Martini, V.,Pedrera, M.,Thakur, N.,Conceicao, C.,Dietrich, I.,Shelton, H.,Ludi, A.,Wilsden, G.,Browning, C.,Zagrajek, A.K.,Bialy, D.,Bhat, S.,Stevenson-Leggett, P.,Hollinghurst, P.,Tully, M.,Moffat, K.,Chiu, C.,Waters, R.,Gray, A.,Azhar, M.,Mioulet, V.,Newman, J.,Asfor, A.S.,Burman, A.,Crossley, S.,Hammond, J.A.,Tchilian, E.,Charleston, B.,Bailey, D.,Tuthill, T.J.,Graham, S.P.,Duyvesteyn, H.M.E.,Malinauskas, T.,Huo, J.,Tree, J.A.,Buttigieg, K.R.,Owens, R.J.,Carroll, M.W.,Daniels, R.S.,McCauley, J.W.,Stuart, D.I.,Huang, K.A.,Howarth, M.,Townsend, A.R.
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Nat Commun, 12:542-542, 2021

PubMed Abstract: There is need for effective and affordable vaccines against SARS-CoV-2 to tackle the ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS-CoV-2. The vaccine is based on the display of coronavirus spike glycoprotein receptor-binding domain (RBD) on a synthetic virus-like particle (VLP) platform, SpyCatcher003-mi3, using SpyTag/SpyCatcher technology. Low doses of RBD-SpyVLP in a prime-boost regimen induce a strong neutralising antibody response in mice and pigs that is superior to convalescent human sera. We evaluate antibody quality using ACE2 blocking and neutralisation of cell infection by pseudovirus or wild-type SARS-CoV-2. Using competition assays with a monoclonal antibody panel, we show that RBD-SpyVLP induces a polyclonal antibody response that recognises key epitopes on the RBD, reducing the likelihood of selecting neutralisation-escape mutants. Moreover, RBD-SpyVLP is thermostable and can be lyophilised without losing immunogenicity, to facilitate global distribution and reduce cold-chain dependence. The data suggests that RBD-SpyVLP provides strong potential to address clinical and logistic challenges of the COVID-19 pandemic.

PubMed: 33483491
DOI: 10.1038/s41467-020-20654-7

実験手法

ELECTRON MICROSCOPY (3.7 Å)